Valuation: Cerus Corporation

Market Cap 455M 408M 380M 345M 650M 43.54B 654M 4.57B 1.79B 22.47B 1.71B 1.67B 72.3B P/E 2026 *
-64.6x
P/E 2027 * -226x
Enterprise Value 460M 412M 384M 349M 657M 44.02B 661M 4.62B 1.81B 22.71B 1.73B 1.69B 73.09B EV / Sales 2026 *
1.85x
EV / Sales 2027 * 1.63x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day-1.74%
1 week-3.42%
Current month-5.04%
1 month-9.24%
3 months-27.56%
6 months+19.58%
Current year+9.71%
1 week 2.2
Extreme 2.2
2.33
1 month 2.2
Extreme 2.2
2.69
Current year 1.62
Extreme 1.62
3.47
1 year 1.38
Extreme 1.38
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 30/06/2026
Chief Tech/Sci/R&D Officer 82 30/06/2015
Director of Finance/CFO 54 03/05/2009
Director TitleAgeSince
Chairman 59 15/03/2026
Director/Board Member 72 23/03/2014
Director/Board Member 51 30/06/2026
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

General Counsel

-30,000 0.0150%
16/07/26 Sell

Chief Executive Officer

-16,666 0.0083%
01/07/26 Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
-1.74%-3.42%+41.25%+79.37% 464M
+2.23%+1.72%-23.20%+12.89% 172B
+3.90%+4.50%-3.69%+28.95% 113B
+1.90%-0.92%-22.49%+11.33% 106B
+0.27%+1.56%-46.32%-11.83% 75.31B
+0.37%+3.22%+2.22%+73.30% 61.8B
+0.96%-0.14%+19.12%+61.64% 52.93B
+2.80%+4.55%+1.25%-26.52% 50.05B
+1.15%-0.59%-14.97%+22.33% 40.81B
-1.38%-0.11% - - 31.81B
Average +1.03%+1.57%-5.20%+27.94% 70.51B
Weighted average by Cap. +1.78%+2.14%-14.37%+19.65%

Financials

2026 *2027 *
Net sales 249M 223M 208M 189M 356M 23.81B 358M 2.5B 978M 12.29B 936M 915M 39.53B 272M 243M 227M 206M 388M 25.96B 390M 2.72B 1.07B 13.39B 1.02B 997M 43.1B
Net income -8.77M -7.85M -7.32M -6.64M -12.52M -838M -12.59M -87.92M -34.42M -432M -32.93M -32.2M -1.39B -1.67M -1.49M -1.39M -1.26M -2.38M -159M -2.39M -16.71M -6.54M -82.22M -6.26M -6.12M -265M
Net Debt 5M 4.48M 4.17M 3.78M 7.14M 478M 7.18M 50.14M 19.63M 247M 18.78M 18.37M 794M -13M -11.64M -10.85M -9.84M -18.56M -1.24B -18.68M -130M -51.04M -641M -48.83M -47.75M -2.06B
Projected Income Statement - Annual - Cerus Corporation
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
12/10/26 US$2.260 -1.74% 1,179,807
09/10/26 US$2.300 +0.88% 787,967
08/10/26 US$2.280 -0.44% 2,419,512
07/10/26 US$2.290 -2.14% 888,398
06/10/26 US$2.340 0.00% 1,608,095
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Ratings Surperformance© - Cerus Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.260USD
Average target price
5.125USD
Spread / Average Target
+126.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cerus Corporation
  1. Stock Market
  2. Stocks
  3. CERS Stock